Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OsteoBiol GTO is a xenogeneic bone grafting biomaterial developed and manufactured by Tecnoss. It is a dual-phase, sticky bone substitute consisting of a mixture of collagenated cortico-cancellous bone granules (porcine/equine origin, 600-1000 µm) and OsteoBiol TSV (Thermally Sensitive Viscoelastic) gel. This combination provides a pre-hydrated, ready-to-use syringe formulation that is easy to apply and stable within the defect site. The material is designed for guided bone regeneration (GBR) in dental and oral surgery, including extraction socket preservation, sinus lifting, and horizontal ridge augmentation. The preserved collagen matrix within the xenogeneic bone facilitates blood clot stabilization and cell invasion, promoting osteoconduction and eventual replacement by native bone tissue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OsteoBiol GTO.